Welcome to Blood Cancer United Newsroom
Get the latest news about how we are creating a world without blood cancers—and improving the quality of life of patients and their families.
Research
Immunitas Therapeutics Announces First Patient Dosed in Phase 1/2a Study of IMT-009
WALTHAM, Mass., January 4, 2023 – Immunitas Therapeutics (“Immunitas”), a clinical stage precision immunotherapy company committed to discovering and …
Research
Apply to the Influential Medicine Providing Access to Clinical Trials (IMPACT) Program
Expanding access to high-quality clinical trials to patients served by community health settings, particularly rural, minority, and/or economically di…
Research
Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million ($57M USD)
Krakow, Poland – December 22, 2022 – Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small mole…
News
FDA Approves the First-in-Class Bispecific Antibody for Treatment of Follicular Lymphoma
“This new treatment has the potential to help patients with this hard-to-treat cancer achieve remission,” says LLS Chief Scientific Officer Dr. Lee Gr…
For all media-related inquiries and interview requests please email
mediarelations@bloodcancerunited.org
A Blood Cancer United representative will respond as soon as possible.
